Cartalax
AED TRIPEPTIDE · KHAVINSON BIOREGULATOR · 3 AA · NOT EPITALON
also: AED · Ala-Glu-Asp · H-Ala-Glu-Asp-OH
Cartalax is the tripeptide Ala-Glu-Asp (AED), developed by Khavinson's St Petersburg group and marketed as a cartilage 'bioregulator'. Published work is confined to organotypic and cell-culture systems — kidney tissue explants, skin fibroblasts, mesenchymal and dental stem cells — with no in vivo cartilage model and no human study. It is frequently and incorrectly listed as AEDG; AEDG is a different, four-residue peptide marketed as Epitalon/Epithalon.
// our evidence grade — unedited
Cartalax is a tripeptide studied only in cell and tissue culture, with no animal outcome study, no human data, and no registered trial; the widespread claim that it is the AEDG tetrapeptide sold as Epitalon is factually wrong, which means much of the marketing evidence attributed to it belongs to a different molecule.
We grade this compound and we sell it. The grade is set against our published criteria before any stocking decision and is not adjusted because it is in the catalogue.
read the full evidence →// specification
| full name | Cartalax (Ala-Glu-Asp, AED) |
| formula | C12H19N3O8 |
| molar mass | 333.29 g/mol |
| purity | ≥ 98% HPLC |
| form | lyophilised powder, sealed vial |
| storage | Lyophilised powder is stored desiccated at -20 °C and protected from light. Once reconstituted, laboratory practice is refrigeration at 2-8 °C for short-term use, or aliquoting and freezing to avoid repeated freeze-thaw cycles. Handling information only; this compound has no approved human use. |
| solubility | Short hydrophilic peptide, readily soluble in sterile or bacteriostatic water and in dilute aqueous buffer. Lot-specific solubility is stated on the certificate of analysis. |
| sequence | Ala-Glu-Asp (AED) |
// select size
crypto payment · research use only · not for human consumption
// others in Healing & Repair